Journal Article

Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting <i>bax</i> and <i>p21</i><sup>CIP</sup> expression

Luciana Tessitore, Annalisa Davit, Ivana Sarotto and Giovanna Caderni

in Carcinogenesis

Volume 21, issue 8, pages 1619-1622
Published in print August 2000 | ISSN: 0143-3334
Published online August 2000 | e-ISSN: 1460-2180 | DOI: http://dx.doi.org/10.1093/carcin/21.8.1619
Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21CIP expression

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics

GO

Show Summary Details

Preview

We investigated whether resveratrol (RV) affects azoxymethane (AOM)-induced colon carcinogenesis, by administering RV (200 μg/kg/day in drinking water) to male F344 rats for 100 days, beginning 10 days before carcinogen treatment (two weekly doses of 15 mg/kg AOM). Aberrant crypt foci (ACF) were isolated and proliferation, apoptosis and expression of the cell cycle genes bax and p21 were determined. RV significantly reduced the number of ACF/colon [25.7 ± 3.6 (mean ± SEM) versus 39.4 ± 3.3 in controls; P < 0.01] and their multiplicity (2.7 ± 0.3 versus 4.9 ± 0.6 in controls; P < 0.01), and also abolished large ACF. In RV-treated rats, bax expression was enhanced in ACF but not in the surrounding mucosa. In both controls and RV-treated rats, proliferation was higher in ACF than in normal mucosa. p21 was expressed in ACF of controls and of RV-treated rats and in normal mucosa of controls, but was lost in normal mucosa of RV-treated animals. In conclusion, the results suggest a protective role of RV in colon carcinogenesis with a mechanism involving changes in bax and p21 expression.

Keywords: ACF, aberrant crypt foci; AOM, azoxymethane; RV, resveratrol.

Journal Article.  2813 words. 

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.